Activation of Latent Oncogenic Viruses as a Form of Targeted Cancer Therapy

Time: 12:00 pm
day: Day Two


  • Outlining the Epstein-Barr virus (EBV), a ubiquitous lymphotropic herpesvirus, associated with a heterogenous group of malignancies.
  • Demonstrating how Nanatinostat induces expression of the EBV protein kinase, BGLF4, which activates the antiviral ganciclovir via phosphorylation to block DNA synthesis and trigger apoptosis.
  • Discussing our phase 1b/2 clinical data which demonstrated promising efficacy and safety in patients with various subtypes of relapsed/refractory Epstein-Barr virus-positive lymphoma